{{Short description|Former Canadian biopharmaceutical company}} {{Infobox company | name = Cangene Corporation | logo = | logo_size = | logo_alt = | logo_caption = | logo_padding = | image = | image_size = | image_alt = | image_caption = | type = | industry = pharmaceutical industry; contract manufacturing industry | fate = Acquired by Emergent BioSolutions | founded = {{start date|1984}} in Winnipeg, Manitoba, Canada | founder = <!-- or: | founders = --> | defunct = {{end date|2014}} | divisions = Cangene bioPharma (CMO) | subsidiaries = }} '''Cangene Corporation''' was a biopharmaceutical company based in Winnipeg, Manitoba, Canada. It was founded in 1984 and specialized in hyperimmunes, contract manufacturing, biopharmaceuticals and biodefense. Cangene was 61% owned by Canadian pharmaceutical giant Apotex and was publicly listed on the TSX under the symbol CNJ.
==Business model== Cangene's business model shifted several times during its existence. There is some consensus that the company came to rely on revenue from United States stockpiling and bioterrorism contracts and did not adequately prepare for the disappearance of this revenue.<ref name="cash2012" /> At one point, the company attempted a shift away from contract manufacturing to research & development, but abandoned this track after about two years and subsequently moved to marketing of ready-for-launch products developed by other companies.<ref name="cash2012" />
==History== Cangene was founded in 1984 and had an employee count of 650 in 2004.<ref name="pharmtech2004" /> In 2009, the number of personnel in the Winnipeg facilities alone was 550, with another 100 in Cangene bioPharma, 35 in its sales force, and about 100 across its plasma collection facilities.<ref name="cash2012" /> By the end of 2011, the overall number of employees was about 700, but significant cuts in personnel were conducted early in 2012.<ref name="cash2012" /><ref name="kirbyson2012">{{cite news | author=Kirbyson, Geoff | date=6 January 2012 | title=Cangene cuts workforce by 20% | work=Winnipeg Free Press | url=http://www.highbeam.com/doc/1P3-2554111981.html | archive-url=https://web.archive.org/web/20150329105810/http://www.highbeam.com/doc/1P3-2554111981.html | url-status=dead | archive-date=29 March 2015 }}</ref> Such cuts were a continuation of a set of personnel reductions which began in mid-2010.<ref name="kirbyson2011">{{cite news | author=Kirbyson, Geoff | date=9 April 2011 | title=Cangene lays off 40 staff; cites dip in U.S. contracts | work=Winnipeg Free Press | url=http://www.highbeam.com/doc/1P3-2315014991.html | archive-url=https://web.archive.org/web/20150329105808/http://www.highbeam.com/doc/1P3-2315014991.html | url-status=dead | archive-date=29 March 2015 }}</ref>
In 2010, Cangene obtained United States distribution rights for WinRho from Baxter, which had held them since 2005.<ref name="bwk2010" /> This was in part to counter declining sales of the product under Baxter, but also as part of the corporate strategy, which called for development its own IVIG product.<ref name="cash2010" /> As both WinRho and the newly conceived product were dependent upon human plasma as source material, Cangene expanded their plasma collection facilities in 2010.<ref name="cash2010" />
Development of the new IVIG product was subsequently cancelled in 2012, representing a strategic turn away from R&D toward marketing in an attempt to return to profitability.<ref name="cash2012" /> Decline in profitability had come in part due to decreased cash flow from a {{currency|500 million}} bioterrorism-related program of work with the U.S. Biomedical Advanced Research and Development Authority.<ref name="cash2012" />
In 2012, the company obtained exclusive United States distribution rights for Episil.<ref name="cash2012" />
In 2013, the company purchased rights to development and commercialization of three drug candidates, recombinant blood clotting factors VIIa, VIII and IX, the latter of which is in clinical trials.<ref name="geneng2013">{{Cite news |author=Staff | date=March 15, 2013 | title=Cangene inks $300+M deal for bankrupt Inspiration's IB1001 | work=Gen. Eng. Biotechnol. News | location=United States | type=paper | volume=33 | issue=6 | page=8 }}</ref>
In February 2014, the company was acquired by Emergent BioSolutions.<ref name="ebs2014pr">{{cite press release | url=http://phx.corporate-ir.net/phoenix.zhtml?c=202582&p=irol-newsArticle&ID=1902315<!--page not in archive.org due to robots.txt--> | title=Emergent BioSolutions Completes Acquisition of Cangene Corporation | publisher=Emergent BioSolutions | date=21 February 2014 | accessdate=17 June 2014 }}</ref>
===Corporate governance=== As of 2010, Paul Brisebois served as the company's vice president for commercial development.<ref name="bwk2010" /> At the time, the company was in the process of expanding its sales force and shifting focus from contract manufacturing to a "strategy to optimize our commercial assets."<ref name="bwk2010" />
In 2011, the company's "longtime CEO", John Langstaff of Winnipeg, resigned and leadership went to John Sedor of Philadelphia as president and CEO.<ref name="cash2013" /><ref name="bwk2013" />
==Operations== Cangene's two manufacturing and plasma collection facilities were located in Winnipeg, Manitoba, Canada.<ref name="pharmtech2004" /><ref name="bwk2013" /> The contract manufacturing subdivision, Celegene bioPharma, maintains facilities in Baltimore, Maryland, United States.<ref name="bwk2013" /> The sales and marketing office was located in Philadelphia, Pennsylvania, United States.<ref name="bwk2013" /> Most of the company's senior leadership were also based in Philadelphia by the time the company was sold in early 2014.<ref name="cash2013" />
==Products== As a result of their biodefense focus, Cangene had three products included in the U.S. Strategic National Stockpile: Heptavalent botulism antitoxin, Vaccinia immune globulin, Anthrax immune globulin.<ref name="bwk2013" /> 2012 revenue from the biodefense products amounted to {{currency|50 million}}.<ref name="bwk2013" /> Cangene also had four approved commercial specialty products: WinRho, HepaGam B, VARIZIG, and episil.<ref name="bwk2013" /> 2012 commercial product revenue was {{currency|44 million}}, while their contract manufacturing revenue was {{currency|33 million}}.<ref name="bwk2013" />
==Cangene bioPharma== Cangene bioPharma is the Baltimore-based contract manufacturing division of Cangene.<ref name="kearney2010" /> As of November 2010, Cangen bioPharma had 100 employees in two facilities,<ref name="pharmtech2004" /> and 30 customers.<ref name="kearney2010" />
From May 2008 to at least November 2010, Cangene bioPharma supplied assembled Fusilev product to Spectrum Pharmaceuticals under a supply agreement.<ref name="kearney2010" /> The agreement was slated to end in May 2013.<ref name="kearney2010" />
==References== {{reflist|33em|refs=
<ref name="bwk2010">{{cite news | author=Staff | title=Cangene assumes U.S. commercialization rights for WinRho SDF | date=5 May 2010 | work=Biotech Week | location=United States | url=http://www.highbeam.com/doc/1G1-225162858.html | archive-url=https://web.archive.org/web/20150329105804/http://www.highbeam.com/doc/1G1-225162858.html | url-status=dead | archive-date=29 March 2015 }}</ref>
<ref name="bwk2013">{{cite news | author=Staff | title=Emergent BioSolutions to Acquire Cangene Corporation | work=Biotech Week | location=United States | date=25 December 2013 | url=http://www.highbeam.com/doc/1G1-353945714.html | archive-url=https://web.archive.org/web/20150329105732/http://www.highbeam.com/doc/1G1-353945714.html | url-status=dead | archive-date=29 March 2015 }}</ref>
<ref name="cash2010">{{cite news | author=Cash, Martin | work=Winnipeg Free Press | title=Cangene Corp. begins transformation project | date=16 June 2010 | url=http://www.highbeam.com/doc/1P3-2058879031.html | archive-url=https://web.archive.org/web/20150329105801/http://www.highbeam.com/doc/1P3-2058879031.html | url-status=dead | archive-date=29 March 2015 }}</ref>
<ref name="cash2012">{{cite news | author=Cash, Martin | work=Winnipeg Free Press | title=Cangene Goes Commercial | date=14 July 2012 | via= | url= }}</ref>
<ref name="cash2013">{{cite news | author=Cash, Martin | date=20 December 2013 | title=Cangene Takeover Might Not Be a Bad Thing | work=Winnipeg Free Press | via= | url= }}</ref>
<ref name="kearney2010">{{cite news | author=Kearney, Brendan | title=Drug-maker Cangene can close for upgrades, says U.S. District Court | work=The Daily Record | location=United States | date=29 November 2010 | url=http://www.highbeam.com/doc/1P2-26901250.html | archive-url=https://web.archive.org/web/20150329105728/http://www.highbeam.com/doc/1P2-26901250.html | url-status=dead | archive-date=29 March 2015 }}</ref>
<ref name="pharmtech2004">{{cite news | author=Staff | title=Cangene Corporation | work=Pharmaceutical Technology | publisher=Advanstar | date=1 December 2004 | url=http://www.highbeam.com/doc/1P3-772522271.html | archive-url=https://web.archive.org/web/20150329105734/http://www.highbeam.com/doc/1P3-772522271.html | url-status=dead | archive-date=29 March 2015 }}</ref>
}}
==External links== * {{Official website|http://www.cangene.com}}
==Further reading== * {{cite web | url=http://www.cangene.com/investor-relations | title=Introduction | publisher=Cangene | accessdate=5 Aug 2013 | url-status=dead | archivedate=21 May 2013 | archiveurl=https://web.archive.org/web/20130521031947/http://www.cangene.com/investor-relations }}
Category:Companies based in Winnipeg Category:Pharmaceutical companies established in 1984 Category:1984 establishments in Manitoba Category:Pharmaceutical companies disestablished in 2014 Category:2014 disestablishments in Manitoba